share_log

TC BioPharm | 8-K: Current report

SEC announcement ·  Mar 6 06:33
Summary by Moomoo AI
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
On February 29, 2024, TC BioPharm (Holdings) PLC, an emerging growth company listed on The Nasdaq Stock Market, reported a significant update to its executive compensation structure. The company's Remuneration Committee approved the issuance of new options to purchase American Depositary Shares (ADSs) to its executive officers and non-employee directors under the 2021 Shares Option Scheme. This move also included the cancellation of all previously issued share options to these individuals. Non-employee directors were granted options to purchase 41,760 ADSs each, while the CFO, Martin Thorp, received options for 177,122 ADSs, and the CEO, Bryan Kobel, was granted options for 381,606 ADSs. The exercise price for these options was set at $1.09 per ADS, equivalent to the closing price on January 31, 2024. All options vested immediately upon issuance. This strategic decision aligns with the company's aim to incentivize its leadership team and align their interests with those of the shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more